The biopharmaceutical industry’s summer doldrums will unofficially come to a close this week thanks to steady gusts of wind from the Food and Drug Administration, plus a slate of presentations in front of scientists and investors.
Some events are more important than others. If you only have time to focus on a few of the stories about to unfold this week, make sure you don’t… Continue reading at Fool.com